Fatal interaction between ritonavir and MDMA

被引：86

作者：

Henry, JA

Hill, IR

机构：

[1] St Marys Hosp, Imperial Coll Sch Med, Acad Dept Accid & Emergency Med, London W2 1NY, England

[2] United Med & Dent Sch Guys & St Thomas Hosp, Dept Forens Med, London SE1 9RT, England

来源：

LANCET | 1998年 / 352卷 / 9142期

关键词：

D O I：

10.1016/S0140-6736(05)79824-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1751 / 1752

页数：2

共 5 条

[1] Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations [J].

Barry, M ;

Gibbons, S ;

Back, D ;

Mulcahy, F .

CLINICAL PHARMACOKINETICS, 1997, 32 (03) :194-209

[2] CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].

BROSEN, K ;

GRAM, LF .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547

[3] TOXICITY AND DEATHS FROM 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) [J].

HENRY, JA ;

JEFFREYS, KJ ;

DAWLING, S .

LANCET, 1992, 340 (8816) :384-387

[4]

ROBERTS L, 1993, J ACCID EMERG MED, V11, P53

[5] THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6) [J].

TUCKER, GT ;

LENNARD, MS ;

ELLIS, SW ;

WOODS, HF ;

CHO, AK ;

LIN, LY ;

HIRATSUKA, A ;

SCHMITZ, DA ;

CHU, TYY .

BIOCHEMICAL PHARMACOLOGY, 1994, 47 (07) :1151-1156

← 1 →